{"disease":{"id":"alk-positive-nsclc","name":"alk positive nsclc"},"drugs":{"marketed":[{"drug_id":"lorlatinib-with-chemotherapy-2","indication_name":"Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) with brain metastases","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorlatinib with chemotherapy 2","generic_name":"lorlatinib-with-chemotherapy-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK","drug_class":"ALK inhibitor","quality_score":40,"revenue":"798","mechanism":""},{"drug_id":"lorlatinib-with-chemotherapy-2","indication_name":"ALK-positive metastatic NSCLC without brain metastases","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorlatinib with chemotherapy 2","generic_name":"lorlatinib-with-chemotherapy-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK","drug_class":"ALK inhibitor","quality_score":40,"revenue":"798","mechanism":""},{"drug_id":"lorlatinib-with-chemotherapy-2","indication_name":"ALK-positive metastatic NSCLC with brain metastases and with or without echinoderm microtubule-associated protein-like 4 (EML4) anaplastic lymphoma kinase (ALK) fusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorlatinib with chemotherapy 2","generic_name":"lorlatinib-with-chemotherapy-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK","drug_class":"ALK inhibitor","quality_score":40,"revenue":"798","mechanism":""},{"drug_id":"ensartinib","indication_name":"ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ensacove","generic_name":"ENSARTINIB","company_name":"Xcovery","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":49,"revenue":null,"mechanism":"Ensartinib works by inhibiting a specific protein that drives the growth of cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04647110","title":"Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.","phase":"","overall_status":"COMPLETED","enrollment_count":549,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT01970865","title":"A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":364,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04009317","title":"Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":260,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT05132218","title":"Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT07491497","title":"A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"TRIANA Biomedicines, Inc.","has_results":false},{"nct_id":"NCT04056572","title":"Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":135,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT03410108","title":"Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03535740","title":"A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Ariad Pharmaceuticals","has_results":true},{"nct_id":"NCT06904547","title":"Resistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCLC","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT06736561","title":"A Multicenter Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Harbin Medical University","has_results":false},{"nct_id":"NCT02393625","title":"Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03672643","title":"Long Term Safety Observation of Crizotinib in Chinese NSCLC Population","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05178511","title":"Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Li Zhang, MD","has_results":false},{"nct_id":"NCT06785584","title":"Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Fujian Medical University Union Hospital","has_results":false},{"nct_id":"NCT07045610","title":"Primary Resistance Mechanisms of ALK TKIs","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT03131206","title":"A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":true},{"nct_id":"NCT05100134","title":"Managed Access Programs for LDK378, Ceritinib","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06834074","title":"Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Nuvalent Inc.","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}